Development of a system to treat and online monitor photodynamic therapy of skin cancer using PpIX near-infrared fluorescence

Garcia, Marlon Rodrigues; Requena, Michelle Barreto; Pratavieira, Sebastião; Moriyama, Lílian Tan; Becker, Marcelo; Bagnato, Vanderlei Salvador; Kurachi, Cristina; Magalhães, Daniel Varela

doi:10.1016/j.pdpdt.2020.101680

Cited by 10 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2020, Garcia et al developed a system to monitor PDT treatment of skin cancer, using luminescence imaging in the red-to-near infrared range (600-750 nm) with protoporphyrin IX ( 35 , Figure 12 ). It was reported that the red excitation light for PDT (407 nm, 120 J/cm², 50 mW/cm²) could hereby be used directly for imaging in vivo (nude mice, A431 xenograft), which generated a substantial fluorescence signal throughout the lesions and allowed for a deeper tissue penetration, as well as continuous monitoring of the skin lesions 85 .…”

Section: Pdt and Optical Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Theranostics with photodynamic therapy for personalized medicine: to see and to treat

Wang,

Staudinger,

Mindt

et al. 2023

Theranostics

View full text Add to dashboard Cite

Photodynamic Therapy (PDT) is an approved treatment modality, which is presently receiving great attention due to its limited invasiveness, high selectivity and limited susceptibility to drug resistance. Another related research area currently expanding rapidly is the development of novel theranostic agents based on the combination of PDT with different imaging technologies, which allows for both therapy and diagnosis. This combination can help to address issues of suboptimal biodistribution and selectivity through regional imaging, while therapeutic agents enable an effective and personalized therapy. In this review, we describe compounds, whose structures combine PDT photosensitizers with different imaging probes - including examples for near-infrared optical imaging, magnetic resonance imaging (MRI) and nuclear imaging (PET or SPECT), generating novel theranostic drug candidates. We have intentionally focused our attention on novel compounds, which have already been investigated preclinically in vivo in order to demonstrate the potential of such theranostic agents for clinical applications.

show abstract

Section: Pdt and Optical Imagingmentioning

confidence: 99%

“… Theranostic agents containing rhodamine, and the photosensitizer protoporphyrin IX for a combined approach of NIR-imaging and PDT 83 - 85 . …”

Section: Figurementioning

confidence: 99%

Theranostics with photodynamic therapy for personalized medicine: to see and to treat

Wang,

Staudinger,

Mindt

et al. 2023

Theranostics

View full text Add to dashboard Cite

show abstract

“…25 Novel monitoring devices, such as the one under development by Garcia and colleagues, to quantify cPDT treatment may increase the rate of adoption by providing clinicians more confidence. 26,27 This specific monitoring device uses a light filter and a digital camera and allows for online monitoring of PpIX excitation through fluorescence to determine appropriate dose. More comprehensive studies are needed to determine the most effective wavelength range or light combination in cPDT.…”

Section: Conventional Photodynamic Therapymentioning

confidence: 99%

Effects of Blue Light on the Skin and Its Therapeutic Uses: Photodynamic Therapy and Beyond

Pieper

Lee

Swali

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fiber-optic fluorescence imaging of BPD before and after PDT, in preclinical studies, demonstrated a method for obtaining immediate response feedback of tumor destruction and prediction of tumor regrowth following treatment. Online monitoring of PDT response has been further characterized by Garcia et al [213] with NIR fluorescence signal of PpIX used to monitor PDT (which notably also provides simultaneous therapeutic effects, as with BPD) of skin cancer. Despite several encouraging preclinical studies, PFD is not a popular option in clinical settings for diagnostic applications mainly due to the existence of fluorophores which have much higher fluorescence quantum yields and hence sensitivity.…”

Section: Detection and Therapy Monitoring In Pdtmentioning

confidence: 99%

Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization — a Thomas Dougherty Award for Excellence in PDT paper

Silva

Saad

Thomsen

et al. 2020

J. Porphyrins Phthalocyanines

View full text Add to dashboard Cite

Photodynamic therapy is a photochemistry-based approach, approved for the treatment of several malignant and non-malignant pathologies. It relies on the use of a non-toxic, light activatable chemical, photosensitizer, which preferentially accumulates in tissues/cells and, upon irradiation with the appropriate wavelength of light, confers cytotoxicity by generation of reactive molecular species. The preferential accumulation however is not universal and, depending on the anatomical site, the ratio of tumor to normal tissue may be reversed in favor of normal tissue. Under such circumstances, control of the volume of light illumination provides a second handle of selectivity. Singlet oxygen is the putative favorite reactive molecular species although other entities such as nitric oxide have been credibly implicated. Typically, most photosensitizers in current clinical use have a finite quantum yield of fluorescence which is exploited for surgery guidance and can also be incorporated for monitoring and treatment design. In addition, the photodynamic process alters the cellular, stromal, and/or vascular microenvironment transiently in a process termed photodynamic priming, making it more receptive to subsequent additional therapies including chemo- and immunotherapy. Thus, photodynamic priming may be considered as an enabling technology for the more commonly used frontline treatments. Recently, there has been an increase in the exploitation of the theranostic potential of photodynamic therapy in different preclinical and clinical settings with the use of new photosensitizer formulations and combinatorial therapeutic options. The emergence of nanomedicine has further added to the repertoire of photodynamic therapy’s potential and the convergence and co-evolution of these two exciting tools is expected to push the barriers of smart therapies, where such optical approaches might have a special niche. This review provides a perspective on current status of photodynamic therapy in anti-cancer and anti-microbial therapies and it suggests how evolving technologies combined with photochemically-initiated molecular processes may be exploited to become co-conspirators in optimization of treatment outcomes. We also project, at least for the short term, the direction that this modality may be taking in the near future.

show abstract

Development of a system to treat and online monitor photodynamic therapy of skin cancer using PpIX near-infrared fluorescence

Cited by 10 publications

References 33 publications

Theranostics with photodynamic therapy for personalized medicine: to see and to treat

Theranostics with photodynamic therapy for personalized medicine: to see and to treat

Effects of Blue Light on the Skin and Its Therapeutic Uses: Photodynamic Therapy and Beyond

Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization — a Thomas Dougherty Award for Excellence in PDT paper

Contact Info

Product

Resources

About